Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
January 2021
in “Journal of The European Academy of Dermatology and Venereology”
TLDR Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
A prospective cohort study involving 77 hospitalized men found that the use of anti-androgens could potentially reduce the severity of COVID-19 outcomes. The study divided the participants into two groups: those who had been on anti-androgens for at least 6 months before hospitalization and those who hadn't. The results indicated a significantly lower rate of ICU admission in the group taking anti-androgens (8%) compared to the group not taking them (58%), even after adjusting for age. Anti-androgens like finasteride, dutasteride, and spironolactone could potentially improve outcomes for men infected with SARS-CoV-2. However, due to the small study size, the authors recommend larger studies for further investigation.
View this study on onlinelibrary.wiley.com →
Cited in this study
research Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
research Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
research Androgen sensitivity gateway to COVID ‐19 disease severity
Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
Related
research Androgenetic alopecia in women and men is not related to COVID‐19 infection severity: a prospective cohort study of hospitalized COVID‐19 patients
Hair loss doesn't affect COVID-19 severity.